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Abstract
Background: The discovery of cell free fetal DNA (cff-DNA) in maternal plasma has brought new insight for noninvasive
prenatal diagnosis. Combining with the rapidly developed massively parallel sequencing technology, noninvasive prenatal
detection of chromosome aneuploidy and single base variation has been successfully validated. However, few studies
discussed the possibility of noninvasive pathogenic CNVs detection.
Methodology/Principal Findings: A novel algorithm for noninvasive prenatal detection of fetal pathogenic CNVs was firstly
tested in 5 pairs of parents with heterozygote a-thalassemia of Southeast Asian (SEA) deletion using target region capture
sequencing for maternal plasma. Capture probes were designed for a-globin (HBA) and b-globin (HBB) gene, as well as
4,525 SNPs selected from 22 automatic chromosomes. Mixed adaptors with 384 different barcodes were employed to
construct maternal plasma DNA library for massively parallel sequencing. The signal of fetal CNVs was calculated using the
relative copy ratio (RCR) of maternal plasma combined with the analysis of R-score and L-score by comparing with normal
control. With mean of 101.936maternal plasma sequencing depth for the target region, the RCR value combined with
further R-score and L-score analysis showed a possible homozygous deletion in the HBA gene region for one fetus,
heterozygous deletion for two fetus and normal for the other two fetus, which was consistent with that of invasive prenatal
diagnosis.
Conclusions/Significance: Our study showed the feasibility to detect pathogenic CNVs using target region capture
sequencing, which might greatly extend the scope of noninvasive prenatal diagnosis.
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Introduction
Over thousands of monogenetic diseases are reported with
known phenotype and molecular mechanism with various
incidences in different regions. Most monogenic diseases are
caused by single base variations, indel or copy number variations
(CNVs). Thalassemia is one of most common monogenetic
diseases in the south of China and Southeast Asia. The genetic
survey showed the frequency of carrier achieves 26.9% fora-
thalassemia and 19.9% for b-thalassemia in Guangxi Zhuang
Autonomous Region [1]. Another study in 471 children with a-
thalassemia found the Southeast Asian (SEA) types is a major type
of a-thalassemia gene deletion with 75.3% of frequency [2]. To
decrease the incidence of these monogenetic diseases, prenatal
diagnosis is wildly used as the most efficient approach in clinical
practices. But traditional sampling approaches for prenatal
diagnosis such as amniocentesis and chorionic villus sampling
(CVS) are invasive and therefore might increase the risk of
miscarriage [3].
The discovery of cell free fetal DNA (cff-DNA) in maternal
plasma opens the door for noninvasive prenatal diagnosis [4].
However, the detection of fetal DNA is very difficult for the vast
background of maternal DNA [5]. Up to now, several studies have
been reported by different groups and demonstrate the high
accuracy of noninvasive prenatal detection of fetal chromosome
aneuploidy [6,7]. Moreover, whole genome sequencing (WGS) of
maternal plasma DNA can recover the fetal specific allele with
over 95% of accuracy, presenting the possibility of monogenetic
detection by maternal plasma [8]. However, the extremely high
cost of whole genome deep sequencing restricts its application in
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clinic practices. Target region deep sequencing, which could
achieve deep sequencing for the interested region with lower cost,
is an alternative approach to detect monogenetic disease
noninvasively [9]. Lo et al. developed an algorithm for noninva-
sive prenatal diagnosis of fetal monogenetic diseases using target
region capture sequencing for single base variations and indels
[10]. Using this method, two fetuses were correctly diagnosed to be
carriers of b-thalassemia. However, there is still lack of effective
approaches to noninvasively detect pathogenic CNVs for fetus,
which is one of the most common causes in monogenetic diseases.
In this study, we developed a novel method for pathogenic
CNVs detection using target region sequencing for maternal
plasma. With much lower cost compared with whole genome
sequencing, a suspected SEA type of homozygous a-thalassemia
deletion in a fetus was successfully detected using our method. It
was the first time for noninvasive prenatal detection of fetal small
size CNVs from maternal heterozygous background.
Results
Clinical Sample and Data Production
Five couples both detected to be SEA type of a-thalassemia
deletion carriers was recruited with informed written consent.
Theoretically the fetus has a possibility of 25% to be Bart’s
Hydrops Syndrom (–SEA/2SEA), Cordocentesis or amniocente-
sis was performed for each pregnant woman to conduct clinical
diagnosis using gap-PCR. Maternal plasma was isolated for
noninvasive prenatal test before cordocentesis and amniocentesis.
Additionally, 12 health participants and 6 pregnant women
normal in a-thalassemia were enrolled as normal control for
genomic DNA (g-DNA) and plasma DNA respectively with
informed written consent.
We performed target region capture sequencing for a total of 15
positive g-DNA samples and 5 positive maternal plasma samples.
The g-DNA data of parents were combined with maternal plasma
data for fetal CNV detection, and the fetal g-DNA data from cord
blood or amniotic fluid sample was taken as feasibility control of
this method. We obtained a median of 26.456106 raw reads for g-
DNA samples. After basic data processing, the effective sequencing
depth for g-DNA varied from 104.156 to 226.326, corresponding
93.23% to 98.67% of coverage for target region (Table 1).
For plasma DNA samples, we obtained a median of
147.986106 raw reads. We applied a double-indexed method to
recover part of false duplication reads besides the conventional
site-recognition method in one plasma sample. 95.66% of
coverage was obtained in double-indexed method, compared with
95.63% of conventional site-recognition method (Table 1). As
expected, the depth of target region displayed a significant
improvement using new approach from 203.216 to 279.916,
implying 37.74% of increasing of useful reads. For the rest
maternal plasma DNA samples, we got an effective sequencing
depth varied from 28.916 to 93.816using traditional data
processing mode, corresponding 97.11% to 98.68% of coverage
in the target region (Table 1). For control samples, the data
production was showed in Table S1.
Cff-DNA Concentration Estimation
The concentration of cff-DNA in maternal plasma was a key
parameter in our method. Using the Bayesian model, we firstly
called the overall loci of maternal and paternal gDNA, and select
the homozygous locus for further analysis. For these five families,
we finally isolated 54 to 706 eligible homozygous SNPs with
different type of allele. Then, we estimated the cff-DNA
concentration in each maternal plasma using these SNPs, which
was 23.41%, 14.29%, 32.27%, 20.28%, and 7.90% (Figure 1 and
Table 2). Our data showed a great fluctuation of cff-DNA
concentration among these sites. The lowest value in family F-1
was only 7.09% while it was up to 63.53% in the highest site, with
a median of 23.41% in the maternal plasma. Moreover, our data
also showed that there was no relationship between fetal
concentration fluctuation and the sequencing depth (Figure 1b).
Pathogenic CNVs Detection
The relative copy ratio (RCR) value, which revealing the
relative depth of a sample, was calculated in each target region and
directly used as indicator for CNV detection. The average value of
RCR (ARCR) on chromosome 16 from 215,400 to 234,700 for
paternal and maternal g-DNA was varied from about 0.43 to 0.58,
which indicated a heterozygous SEA type of a-thalassemia
deletion (Figure 2). In addition, the ARCR value for fetal g-
DNA that close to 0 would strongly suggest a homozygous deletion
in the same region, close to 0.5 suggest a heterozygous deletion,
and close to 1 suggest no deletion. This result was consistent with
the clinical result of gap-PCR. The RCR values of other four
families were showed in Figure S1.
To further ensure the genotypes of each region, we defined two
statistics, R-score and L-score, to detect the pathogenic CNVs. R-
score was defined as the negative logarithmic of the quotient
between the rank of test region and the total number of target
regions. It revealed the deviation of certain region in the tested
sample. In the case of deletion, we set the cutoff as 1.3 (a=0.05),
the larger R-score stands for a higher significance. Meanwhile, we
also recruited a binary assumption strategy to determine the CNV
genotypes. The L-score was the natural logarithm of odd ratio
between these two statistics tests of mutually exclusive assump-
Table 1. Performance of target region capture sequencing.
Sample Reads (M) Data (MB)
Alignment
(%)
Coverage
(%) Depth
MO-1 3.05 0.27 91.39 93.57 135.92
FA-1 2.37 0.21 88.77 95.30 104.15
FT-1 2.71 0.24 89.05 93.23 124.62
MP-1 128.89 11.59 93.58 95.63 203.21
MP-1(Duo-index) 128.89 11.59 93.58 95.66 279.91
MO-2 30.35 2.73 92.10 98.36 174.87
FA-2 22.09 1.99 92.90 97.14 135.81
FT-2 33.92 3.05 89.36 98.51 176.90
MP-2 141.91 12.78 95.34 98.61 62.28
MO-3 30.83 2.77 93.14 98.36 131.22
FA-3 33.04 2.97 93.31 97.43 148.44
FT-3 22.66 2.04 92.99 98.32 104.64
MP-3 145.86 13.12 95.28 98.68 44.75
MO-4 39.81 3.58 91.82 98.67 226.32
FA-4 28.02 2.52 92.19 97.30 176.12
FT-4 28.75 2.59 89.97 97.34 117.40
MP-4 188.27 16.94 89.16 97.56 93.81
MO-5 34.61 3.46 94.65 98.61 174.67
FA-5 43.09 4.31 94.20 97.27 180.79
FT-5 41.39 4.14 91.54 97.46 176.58
MP-5 134.99 12.14 95.24 97.11 28.91
doi:10.1371/journal.pone.0067464.t001
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tions, representing the significance of expected CNV genotype by
comparing to the control samples (Material and Methods). In the
deletion region mentioned above, both the R-score and L-score
were calculated.
We firstly detected that all of the five pair of parents located in
the quadrant of heterozygous deletion, one of the fetuses located in
the quadrant of homozygous deletion, two located in the
heterozygous quadrant, and two located in the normal quadrant
(Figure 3a, b), which was consistent with the result from RCR
calculation.
Combined with the information of fetal concentration, we also
classified all five samples into three subgroups, one located in the
quadrant of homozygous deletion, two located in the heterozygous
quadrant, and two located in the normal quadrant (Figure 3c, d),
which was consistent with the result of fetal gDNA. Our data
showed that the fetal pathogenic deletion could be detected using
our bioinformatics method through maternal plasma target region
sequencing.
Discussion
Since the discovery of cff-DNA in maternal plasma, it has long
been expected to noninvasive prenatal detection for fetal
aneuploidies, even single base mutations and pathogenic CNVs.
Until recently the noninvasive prenatal detection for chromosome
aneuploidy comes to reality with the rapid development of
massively parallel sequencing [6,7] which also makes pathogenic
CNVs detection possible. In this study, we developed a novel
method based on target region capture sequencing to detect the
fetal pathogenic CNVs noninvasively.
In our study, the target region was less than 1.5M bp, about 1/
2,000 of human genome. With a mean depth of lower than 3006
in the target region of maternal plasma, the fetal deletion status in
HBA region was successfully detected using our method. Since it
would cost about $41 for generating 1GB sequencing reads at
present [11], our method was very cost effective. Of course, this
cost would be further reduced as the innovation of the Third-
generation sequencing technology.
The limited starting DNA fragment in plasma is a key obstacle
to get enough deep sequencing data for distinguishing fetal
genotype. Here we set up a double-indexed DNA library
construction approach and determined the duplicated sequencing
reads by the barcodes at each ends of the reads, which could
dramatically increase the ratio of useful sequencing reads. This
approach has been reported to effectively reduce bias produced
during amplification [12]. Double indexing has been proved to be
extremely effective to overcome inaccuracies in multiplex
Figure 1. Fetal concentration calculation in maternal plasma. Fetal concentration in maternal plasma was calculated using both paternal and
maternal homozygous but different type of loci. (a) Gene typing result of 478,685 loci were acquired for both parents. A total of 476,896+297 loci
were homozygous for the father and 476,773+297 for the mother. There were 297 loci was homozygous in both parents but with different type and
were used for fetal concentration calculation in maternal plasma. (b) Cff-DNA concentration and sequencing depth for each of the 297 loci.
doi:10.1371/journal.pone.0067464.g001
Table 2. SNP calling and cff-DNA concentration.
Family Father Mother Effective loci Gestational age cff-DNA Conc. (%)
heterozygote homozygote heterozygote homozygote
F-1 1,492 477,193 1,615 477,070 297 30+6 23.4166.95
F-2 2,760 1,009,442 2,970 1,009,232 553 19+1 14.2967.76
F-3 1,613 579,525 1,777 579,361 282 20+3 32.27613.95
F-4 2,843 1,167,315 3,262 1,166,896 706 17+2 20.2868.01
F-5 190 73,498 223 73,465 54 19 7.9067.23
The color-coded points and lines showed the RCRs distribution of the target regions on HBA gene. RCR value of 0 means a homozygous deletion, 0.5 mean a
heterozygous deletion and 1.0 mean normal. The orange broken line represented the mean RCR in maternal plasma. (Gray, 4 plasma control samples respectively; Blue,
g-DNA from paternal blood; Red, g-DNA from maternal blood cells; Orange, cell free DNA from maternal plasma; Green, g-DNA from fetal amniotic fluid). (a, F-2; b, F-3; c,
F-4; d, F-5).
doi:10.1371/journal.pone.0067464.t002
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sequencing on the Illumina sequencer platform [13]. Conventional
site-recognition method filters duplication reads with same start
point and end point introduced by over amplification in PCR
procedure, which could mistakenly lose part of originally same
reads or keep the real duplicated reads if there was a sequencing
error at the end of the reads. The double-indexed approach
showed a 37.74% of increasing for effective depth of target region,
displaying its great potential to overcome the limitation of starting
materials in plasma.
Fetal concentration in maternal plasma was another important
factor to make it difficult for fetal variation detection. As our data
showed that the fetal DNA was only a tiny part in maternal plasma
and the concentration fluctuated greatly in different sites. As a
result, the fetal CNVs with small size would be much more difficult
to be detected, especially for maternal sauce variations. To solve
this problem, we developed a new bioinformatics algorithm that
based on plasma high-depth sequencing. In this study, we
employed target region capture sequencing instead of WGS as
reported by previous studies [9]. The advantage of target region
capture sequencing is cost-effective and labor-saving. In our study
only one tenth of sequencing data was required to generate for
analysis compared with WGS, but the sequencing depth for the
target region was ten times higher. Most importantly, it is feasible
to get the exactly bound and size of CNVs.
It is very difficult to directly detect small size of fetal CNVs from
maternal plasma, especially in maternal heterozygous background.
Our data has showed great variation of the fetal concentration in
maternal plasma and the variation won’t be eliminated with
higher sequencing depth (Figure 1b). This variation will also
greatly affect the accuracy of fetal CNVs detection. To solve this
problem, we used 12 control samples to adjust the data variation in
gDNA samples and 6 control samples to adjust the data variation
in maternal plasma samples. Then we use the ARCR value to
detect if there is a CNV and the L-score and R-score to further
confirm the CNV status. At last, the size of the CNVs detected
from the maternal plasma was decided by combing the result of
the parents.
However, there were still limitations for our study. The
maternal plasma samples were mostly from late pregnancy due
to the inconvenient of sample collection, which showed a high
concentration of fetal DNA. Although the fetal a-thalassemia
deletion (–SEA/2SEA) status had been successfully detected, the
method needs to be tested with more samples at earlier gestational
age. To improve the detection accuracy, more control samples are
needed in future study. Moreover, the capture specificity for
plasma DNA was much lower than g-DNA, which might be
related with its fragment size. Further experimental optimization is
required in the future.
In conclusion, our study could figure out the fetal deletion
related with a-thalassemia from the maternal heterozygous
background. This result showed the feasibility of fetal pathogenic
CNVs detection using target region capture sequencing of
maternal plasma with our novel bioinformatics method.
Materials and Methods
Clinical Samples
Five couples were recruited from the First Affiliated Hospital of
Sun Yatsen University with informed written consent. Both the
pregnant women and their husbands were detected to be –SEA
type of a-thalassemia deletion carriers by gap-PCR. To make a
prenatal diagnosis, amniocentesis or cordocentesis was performed
at 30+6, 19+1, 20+3, 17+2, and 19 gestational weeks respectively,
and its result was considered as the golden standard traditionally
for prenatal diagnosis. Twelve health participants and 6 pregnant
women normal in a-thalassemia were enrolled as normal control
with informed written consent. Also, this study was approved by
the institutional review board of BGI-Shenzhen and conducted in
accordance with the Declaration of Helsinki.
Probes Design
The fetal pathogenic CNV detection was based on our novel
bioinformatics method using maternal plasma target region
sequencing. Considering the tremendous impact of cff-DNA
concentration on fetal pathogenic CNVs detection, target region
was consisted by two parts. The gene regions of a-globin (HBA)
and b-globin (HBB) gene and 100 bp upstream and downstream
of the gene region was firstly included, and then a total of 4,525
SNPs were selected to calculate the exact concentration of cff-
DNA in maternal plasma. These SNPs were selected from 22
autosomes with the minor allele frequency (MAF) over 0.4 in the
dbSNP Build 135. These designed probes totally covered
761,159 bp of human reference genome (HG19, NCBI build
37). This version called Mini-I was used for our samples from
family F-1 and the control sample CG-1, CG-2, CG-3, CP-1 and
CP-2. For better coverage of the HBA and HBB gene, we designed
an updated version called Mini-II, which was not only covered the
HBA and HBB gene region and 4,525 SNPs, but also the 100 K
bp region upstream and downstream of the two genes. Mini-II
totally covered 1,508,117 bp of human reference genome (HG19,
NCBI built 37), and was used in family F-2, F-3, F-4, F-5 and the
other control samples.
Sample Preparation and Sequencing
Genomic DNA (g-DNA) of parents and fetus extracted from
peripheral blood and umbilical cord blood and amniotic fluid was
Figure 2. The RCR distribution of target region on HBA. The
color-coded points and lines showed the RCRs distribution of the target
regions on HBA gene in F-1. RCR value of 0 mean a homozygous, 0.5
mean a heterozygous and 1.0 mean normal. The orange broken line
represented the mean RCR in maternal plasma. (Gray, 2 control samples
respectively; Blue, g-DNA from paternal blood; Red, g-DNA from
maternal blood cells; Orange, cell free DNA from maternal plasma;
Green, g-DNA from fetal amniotic fluid).
doi:10.1371/journal.pone.0067464.g002
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fragmented by the sonicator. After end blunted, all fragments were
added an ‘‘A’’ tail for the ligation with adaptors. A 6 bp or 8 bp
barcode was added to each sample during 12 cycles of PCR for
multiple sequencing.
Maternal plasma was isolated using two-step centrifugation
protocol [14]. 100 ul maternal plasma was used for DNA
extraction and the DNA was fragmented by nature instead of
sonication. After ‘‘A’’ tailing, adaptors were also added to each
ends of the DNA fragments. For the maternal plasma DNA from
Figure 3. The R-sore and L-score of parental CNV detection using genome DNA and noninvasive fetal CNV detection using
maternal plasma. (a, b), The R-score (y-axis) and L-score (x-axis) of each target region using paternal (blue) and maternal (red) g-DNA were
illustrated as scatter points. The quadrants of normal (copy number= 2), heterozygous deletion (copy number= 1), homozygous deletion (copy
number = 1) and low-confident calling are labeled in the figure. The L-score in (a) was the odd ratio of normal and heterozygous deletion, and in (b)
was the odd ratio of heterozygous deletion and homozygous deletion. (c, d), The R-score (y-axis) and L-score (x-axis) of each target region using
maternal plasma (orange) were illustrated as scatter points. The quadrants of fetal normal (copy number = 2), fetal heterozygous deletion (copy
number = 1), fetal homozygous deletion (copy number = 0) and low-confident calling are labeled in the figure. The L-score in (c) was the odd ratio of
fetal normal and fetal heterozygous deletion, and in (d) was the odd ratio of fetal heterozygous deletion and fetal homozygous deletion. The shapes
of scatters represented the different family. (‘‘*’’, F-1; ‘‘+’’ F-2; Square, F-3; Round, F-4; Diamond, F-5.).
doi:10.1371/journal.pone.0067464.g003
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family F01, different from adaptors adding to g-DNA, these
adaptors were embedded with an 11 bp sequence barcode. There
were a total of 384 different barcodes randomly added to each end
of each DNA fragment, which could generate 3846384 combi-
nations of labels for original maternal-fetal DNA. Then another
6 bp index was introduced during a 17 cycles of PCR for multiple
sequencing. For the other four maternal plasma DNA samples, the
adaptors was the same as the gDNA sample, and the 8 bp barcode
was added to each sample through a 17 cycles of PCR.
Libraries were qualified by DNA 1000 kit on the Agilent 2100
Bioanalyzer to measure the insert size and quantified by real-time
PCR. 3 ug DNA libraries were hybridized with the probes at 65uC
for 22 hours. DNA fragments that binding to the probes was eluted
and enriched by PCR. Captured DNA libraries were conducted
90 bp paired-end index sequencing on the Illumina HiseqTM 2000
sequencer according to the manufacturer’s instructions. All of the
sequencing raw data had been submitted to NCBI SRA (http://
www.ncbi.nlm.nih.gov/sra) and the Submission ID was SRA
065986.
Alignment and Duplication Reads Removal
Short reads were firstly mapped to the human reference (HG19,
NCBI built 37) using SOAP2 [15]with parameters of ‘-v 5–r 1-s
40-l 40’ to select reads with less than one mismatch alignment.
To remove the effect of duplication reads on CNVs detection,
we set up a strict criterion to remove duplicated reads introducing
from PCR procedure using previous reported UID strategy [12].
For the plasma DNA library constructed using a mixed adaptor
with 384 different barcode, the read were considered as
duplication, when 1) with the same type of barcode in both reads,
and 2) with same starting and end position. For the other samples,
the reads meet the condition 2) would be considered as
duplication. Only one of them was reserved for the following
analysis. Besides that, we also filter regions with less than 106
depth in control samples, which might be related with poor
capture efficiency.
Estimation of cff-DNA Concentration
When we detected the genotype of parents in target region, we
used a Bayesian statistical model based on the sequencing depth of
each bases. Only different type of homozygous SNPs in both
parents was isolated to calculate the fetal concentration in
maternal plasma. The formula wasf~
2dfather
dmotherzdfather
, where f stood
for the cff-DNA concentration in maternal plasma, dfather and
dmotherstood for the depth of allele from father and mother
respectively. This concentration of cff-DNA would be used for
detecting fetal genotype in maternal plasma.
Fetal CNV Detection
We developed a novel algorithm to identify the fetal CNV
combining cff-DNA concentration and sequencing depth in target
region (In this case, target region is a-thalassemia related regions
described above). The algorithm was mainly consisted of two tests,
R-score revealing deviations in the tested sample and L-score
representing the probability of fetal CNV comparing to the control
samples.
Basic statistics. Before CNV detection, we first defined several
basic statistics, including the sequence depth of the i-th base of
tested sample (di,test) and control sample (di,control ). And the relative
copy ratio (RCR) was defined as RCRi,test~
di,test=Dtest
di,control=Dcontrol
, where
Dtestand Dcontrol stood for the average sequence depth of test and
control sample respectively. Theoretically, RCR represents the
CNV genotype of each site in the tested sample. Also, we defined
the average sequence depth of each target region (ARCR) as a
more stable statistics following ARCRtr,test~
1
ntr
P
i[tr
RCRi,test (tr
was short for ‘‘target region’’, ntr stood for the total base number in
this target region). ARCRs of Other sequenced regions except the
target region were also calculated.
R-score. R-score is defined as the negative logarithmic
probability as R{scorei~{log10 Pr (ARCRvARCRtr,test)ð Þ. In
calculation, we obtained R-score as the quotient between the rank
of ARCRi,test (ranked by algebraic value, from lower value to
higher value) and the total number of sequenced regions. For
example, if the rank of a tested region is 10, and there are 1000
sequenced regions, the R-score of this region will be
R{scorei~{log10(9=1000)~2:046. R-score represented the
relative relationship between ARCRs, showing their deviation in
the tested sample. For example, bigger R-score stands for smaller
ARCR, which indicates a potential deletion. In the case of
deletion, R-score larger than 1.30 (equals to
Pr (ARCRvARCRi,test)~a~0:05) was elected up as one of the
cutoff.
L-score. In this test, we recruited a binary assumption strategy
to determine the fetal CNV genotype. The L-score was the odd
ratio between these two statistics tests of mutually exclusive
assumptions, representing the significance of fetal CNV by
comparing to the control samples. For better understanding, we
took the detection of fetal heterozygous and homozygous deletion
as examples. Firstly, we assumed the fetal CNV genotype of this
target region was heterozygous deletion (CNfetal~1, CN was short
for copy number). The expected copy ratio (ECR) of this region
was calculated with the maternal CNV genotype and cff-DNA
concentration.
ECRi~ 1{eð ÞCNi,maternalzeNi,fetal
 
=2
.
RCR value of each site in this region in control samples was
normalized to heterozygous deletion. The mean value and
standard deviation of all RCRs were calculated as following:
mean~
1
ncontrol :ntr
X
j[control
X
i[tr
RCRi,jRi
sd~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
ncontrol :ntr{1
X
j[control
X
i[tr
RCRi,j :ECRi{mean
 2s
Heterozygous deletion like hood value l was then calculated.
l~
X
i[tr
RCRi,test{mean
sd
 2
*x2(ntr)
Secondly, we assumed the fetal copy number of this target
region was homozygous deletion (CN ’fetal~0). The procedure is
totally same as heterozygous assumption.
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ECR’i~ 1{eð ÞCNi,maternalze:CN ’i,fetal
 
2
.
mean’~
1
ncontrol :ntr
X
j[control
X
i[tr
RCRi,j :ECR’i
.
sd ’~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
ncontrol :ntr{1
X
j[control
X
i[tr
RCRi,j :ECR’i{mean
 2s
.
l’~
X
i[tr
RCRi,test{mean’
sd ’
 2
*x2(ntr):
Finally, L-score is defined as the logarithmic quotient between l
and l9 as following formula:
L{score~ ln l=l’ð Þ
Theoretically, smaller like hood value l represent higher
similarity between the real fact and the assumption. L-score can
represent the deviation of tested sample comparing to controls as
CNV. In this sample, L-score was elected up to distinguish fetal
heterozygous (L-score,0) and homozygous deletion (L-score.0).
Similar detection could be applied to discriminate between
heterozygous deletion and normal genotype.
Supporting Information
Figure S1 The RCR distribution of target region on
HBA. The color-coded points and lines showed the RCRs
distribution of the target regions on HBA gene. RCR value of 0
means a homozygous deletion, 0.5 mean a heterozygous deletion
and 1.0 mean normal. The orange broken line represented the
mean RCR in maternal plasma. (Gray, 4 plasma control samples
respectively; Blue, g-DNA from paternal blood; Red, g-DNA from
maternal blood cells; Orange, cell free DNA from maternal
plasma; Green, g-DNA from fetal amniotic fluid). (a, F-2; b, F-3; c,
F-4; d, F-5).
(TIF)
Methods S1 Supplementary Methods.
(DOC)
Table S1 Performance of target region capture se-
quencing of control.
(DOCX)
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